Published in J Virol on October 01, 2001
Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol (2004) 1.44
Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. PLoS One (2015) 1.39
Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol (2005) 1.02
Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol (2006) 0.97
Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol (2006) 0.95
Every breath you take: the impact of environment on resident memory CD8 T cells in the lung. Front Immunol (2014) 0.90
Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J Virol (2004) 0.90
Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection. PLoS One (2013) 0.88
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther (2010) 0.84
Engineering influenza viral vectors. Bioengineered (2012) 0.83
Immunogenicity of a recombinant influenza virus bearing both the CD4+ and CD8+ T cell epitopes of ovalbumin. J Biomed Biotechnol (2011) 0.77
Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J (2014) 0.77
Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin. Nanomedicine (2015) 0.75
Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A (1999) 14.90
Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69
Rescue of influenza A virus from recombinant DNA. J Virol (1999) 11.54
Amplification, expression, and packaging of foreign gene by influenza virus. Cell (1989) 11.21
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 9.81
High gradient magnetic cell separation with MACS. Cytometry (1990) 6.69
The gene structure and replication of influenza virus. Annu Rev Biochem (1983) 4.30
Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A (2000) 3.95
Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology (2001) 3.76
Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature (1995) 3.61
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci U S A (1996) 2.47
Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol (1998) 2.42
Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med (1996) 2.30
Expression of a foreign protein by influenza A virus. J Virol (1994) 2.28
Type I IFN modulates innate and specific antiviral immunity. J Immunol (2000) 2.26
Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol (1994) 1.90
Interactions of HIV-1 NEF with cellular signal transducing proteins. Front Biosci (2000) 1.75
Influenza A virus-induced IFN-alpha/beta and IL-18 synergistically enhance IFN-gamma gene expression in human T cells. J Immunol (1998) 1.71
Infectious influenza A and B virus variants with long carboxyl terminal deletions in the NS1 polypeptides. Virology (1987) 1.68
The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol (2000) 1.65
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 1.64
The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol (1989) 1.62
Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol (1995) 1.45
Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. J Clin Invest (1992) 1.43
Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol (1996) 1.38
Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine (1999) 1.37
Selective nuclear export of viral mRNAs in influenza-virus-infected cells. Trends Microbiol (2000) 1.33
Induction of antibody-secreting cells and T-helper and memory cells in murine nasal lymphoid tissue. Immunology (1996) 1.31
Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol (2000) 1.31
Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus. J Virol (2000) 1.25
A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNgamma-producing T cells. J Immunol Methods (1999) 1.21
Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci U S A (1998) 1.16
Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol (1999) 1.13
Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int Immunol (1995) 1.10
Regions of human immunodeficiency virus type 1 nef required for function in vivo. J Virol (1998) 1.09
Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. Virology (1998) 1.07
Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis (1998) 1.03
Development of novel influenza virus vaccines and vectors. J Infect Dis (1997) 1.03
A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection. Infect Immun (1998) 1.02
Influenza virus vectors. Biologicals (1995) 1.01
Protein synthesis shut-off induced by influenza virus infection is independent of PKR activity. J Virol (2000) 1.00
A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production. Wien Klin Wochenschr (1999) 0.96
In vivo derived HIV-1 nef gene products are heterogeneous and lack detectable nucleotide binding activity. AIDS Res Hum Retroviruses (1992) 0.93
Immunological variation and immunohistochemical localization of HIV-1 Nef demonstrated with monoclonal antibodies. AIDS (1992) 0.93
Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J Virol (1999) 0.92
Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein. J Virol (1994) 0.92
The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. Virology (2000) 0.90
Comparison of in vitro immunostimulatory potential of live and inactivated influenza viruses. Hum Immunol (2000) 0.89
Expression of the nonstructural protein NS1 of equine influenza A virus: detection of anti-NS1 antibody in post infection equine sera. J Virol Methods (1997) 0.87
Transfectant influenza viruses as antigen delivery vectors. Adv Virus Res (2000) 0.86
Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology (2000) 0.85
Use of synthetic peptides for the detection of antibodies against the nef regulating protein in sera of HIV-infected patients. AIDS (1989) 0.84
Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes. Res Virol (1998) 0.82
Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization. Virology (2000) 0.81
Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression. AIDS Res Hum Retroviruses (1999) 0.80
New perspectives in mucosal immunity with emphasis on vaccine development. Semin Hematol (1993) 0.79
Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine. Dev Biol Stand (1994) 0.79
High-resolution global maps of 21st-century forest cover change. Science (2013) 17.90
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 10.75
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 9.81
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2001) 5.38
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol (1994) 3.49
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity (1999) 2.67
Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol (1998) 2.42
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30
Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS (1996) 2.26
Efficient transformation of Agrobacterium spp. by electroporation. Nucleic Acids Res (1989) 2.15
The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J Immunol Methods (1988) 2.04
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol (1998) 2.03
Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol (2001) 1.99
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol (1998) 1.87
Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res Hum Retroviruses (1998) 1.86
Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol (1996) 1.85
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol (1998) 1.51
Pilot scale production of a human monoclonal antibody against human immunodeficiency virus HIV-1. J Biochem Biophys Methods (1990) 1.46
HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9. AIDS (1992) 1.29
Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol (2001) 1.28
Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses (1997) 1.26
Subtractive hybridization of mRNA from early passage and senescent endothelial cells. Exp Gerontol (2000) 1.16
Baculovirus surface display: construction and screening of a eukaryotic epitope library. Nucleic Acids Res (1998) 1.12
Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. Biotechnol Bioeng (2000) 1.11
Plant protein hydrolysates: preparation of defined peptide fractions promoting growth and production in animal cells cultures. Biotechnol Prog (2000) 1.09
Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies. J Chromatogr (1989) 1.07
Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. Eur J Pharm Sci (2001) 1.04
Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol (2001) 1.03
Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis (1998) 1.03
Selective retention of viable cells in ultrasonic resonance field devices. Biotechnol Prog (1996) 0.99
Use of health information systems in the Russian federation in the assessment of environmental health effects. Environ Health Perspect (2000) 0.96
Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? J Med Primatol (2001) 0.95
Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol (2002) 0.95
Determination of liposome size distribution by flow cytometry. Cytometry (2000) 0.94
Expression of foreign proteins on the surface of Autographa californica nuclear polyhedrosis virus. Biotechniques (1997) 0.94
Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting. Biotechnol Bioeng (2001) 0.93
The use of macroporous gelatin carriers for the cultivation of mammalian cells in fluidised bed reactors. Cytotechnology (1990) 0.89
Growth and production kinetics of human x mouse and mouse hybridoma cells at reduced temperature and serum content. J Biotechnol (1992) 0.89
A host restriction-based selection system for influenza haemagglutinin transfectant viruses. J Gen Virol (1998) 0.89
An in vitro test system for thyroid hormone action. Anal Biochem (1996) 0.89
Extensive NMRD studies of Ni(II) salt solutions in water and water-glycerol mixtures. J Magn Reson (2008) 0.88
Stability of von Willebrand factor secretion in different human endothelial hybrid cell lines. Cytotechnology (1992) 0.86
Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) (2006) 0.84
Validation of the modified hemagglutination inhibition assay (mHAI), a robust and sensitive serological test for analysis of influenza virus-specific immune response. J Clin Virol (2013) 0.84
Search for additional influenza virus to cell interactions. Glycoconj J (2006) 0.83
Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol Immunol (1998) 0.83
Direct heterogeneous electron transfer of recombinant horseradish peroxidases on gold. Faraday Discuss (2000) 0.83
Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy. Curr Med Res Opin (2009) 0.83
Engineered gene for Escherichia coli alkaline phosphatase for the construction of translational fusions. Nucleic Acids Res (1990) 0.83
Expanding baculovirus surface display. Modification of the native coat protein gp64 of Autographa californica NPV. Eur J Biochem (2000) 0.83
A novel ultrasonic resonance field device for the retention of animal cells. Biotechnol Prog (1994) 0.82
Optimization of sorting conditions for the selection of stable, high-producing mammalian cell lines. Biotechnol Prog (1999) 0.82
Establishment of human fibroma cell lines from a MEN1 patient by introduction of either hTERT or SV40 early region. Int J Oncol (2005) 0.82
Flow cytometry and two-dimensional electrophoresis (2-DE) for system evaluation of long term continuous perfused animal cell cultures in macroporous beads. Cytotechnology (1992) 0.82
Modular integrated fluidized bed bioreactor technology. Biotechnology (N Y) (1991) 0.82
Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain. Drugs Exp Clin Res (1992) 0.81
Human endothelial cell lines established by mutated forms of the simian virus 40 large T oncogene. J Biotechnol (1997) 0.81
Specificity of neuraminidase activity from influenza viruses isolated in different hosts tested with novel substrates. Arch Virol (2004) 0.81
HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. AIDS (1993) 0.81
Localization of fruit tree viruses by immuno-tissue printing in infected shoots of Malus sp. and Prunus sp. J Virol Methods (1995) 0.80
Optimization of baculovirus transduction on FreeStyle293 cells for the generation of influenza B/Lee/40. Mol Biotechnol (2006) 0.80
Preparative purification of human monoclonal antibody isoforms in a multi-compartment electrolyser with immobiline membranes. J Chromatogr (1990) 0.80
HIV-1 gp41 shares a common immunologic determinant with human T, B and monocyte cell lines. Immunol Lett (1994) 0.80
Interaction between a Fab fragment against gp41 of human immunodeficiency virus 1 and its peptide epitope: characterization using a peptide epitope library and molecular modeling. Protein Eng (1995) 0.80
Coat protein mediated resistance to Plum Pox Virus in Nicotiana clevelandii and N. benthamiana. Plant Cell Rep (1992) 0.79
Purification of human recombinant superoxide dismutase by isoelectric focusing in a multicompartment electrolyzer with zwitterionic membranes. Electrophoresis (1994) 0.79
Expression of a human monoclonal anti-HIV-1 antibody in CHO cells. Ann N Y Acad Sci (1991) 0.79
A genetically engineered fusion protein with horseradish peroxidase as a marker enzyme for use in competitive immunoassays. Anal Chem (2001) 0.79
Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer. J Liposome Res (2006) 0.79
Changes during subclone development and ageing of human antibody-producing recombinant CHO cells. J Biotechnol (1999) 0.79
Optimization of recombinant gene expression in Escherichia coli. Ann N Y Acad Sci (1996) 0.78
Analysis of changes during subclone development and ageing of human antibody-producing heterohybridoma cells by northern blot and flow cytometry. J Biotechnol (1999) 0.78
The human monocyte cell line U937 binds HIV-1 gp41 by proteins of 37, 45, 49, 62 and 92 kDa. Immunol Lett (1993) 0.78
HIV-1 gp41 enhances major histocompatibility complex class I and ICAM-1 expression on H9 and U937 cells. Int Arch Allergy Immunol (1994) 0.78
Flow cytometric analysis of metabolic stress effects due to recombinant plasmids and proteins in Escherichia coli production strains. Metab Eng (1999) 0.78
Somatic embryogenesis of Prunus subhirtella autumno rosa and regeneration of transgenic plants after Agrobacterium-mediated transformation. Plant Cell Rep (1995) 0.78
Rational design of an improved induction scheme for recombinant Escherichia coli. Biotechnol Bioeng (1999) 0.78
Cytokine activity assay by means of proliferation measured in plane convex microtiter wells. J Biochem Biophys Methods (1996) 0.77
Production kinetics of monoclonal antibodies. Dev Biol Stand (1985) 0.77
Isolation of human monoclonal antibody isoproteins by preparative isoelectric focusing in immobilized pH gradients. J Biochem Biophys Methods (1989) 0.77
HIV-1 gp41 binds to several proteins on the human B-cell line, Raji. Mol Immunol (1993) 0.77